Glasdegib (CAS 1095173-27-5)
Alternate Names:
Glasdegib PF-04449913 PF 04449913 1-((2R,4R)-2-(1H-benzo[d]iMidazol-2-yl)-1-Methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
CAS Number:
1095173-27-5
Molecular Weight:
374.40
Molecular Formula:
C21H22N6O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Glasdegib (CAS 1095173-27-5) References
- An evaluation of glasdegib for the treatment of acute myelogenous leukemia. | Thomas, X. and Heiblig, M. 2020. Expert Opin Pharmacother. 21: 523-530. PMID: 32027196
- Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. | Cortes, JE., et al. 2020. Leuk Lymphoma. 61: 3287-3305. PMID: 32967493
- Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome. | Tavares, M., et al. 2021. Ann Hematol. 100: 837-839. PMID: 33001280
- Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists. | Relias, V., et al. 2021. J Oncol Pharm Pract. 27: 658-672. PMID: 33215562
- Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers. | Shaik, N., et al. 2021. Cancer Chemother Pharmacol. 87: 241-250. PMID: 33388951
- Updates on targeted therapies for acute myeloid leukaemia. | Kayser, S. and Levis, MJ. 2022. Br J Haematol. 196: 316-328. PMID: 34350585
- Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue. | Peklar, B., et al. 2022. Pharmaceutics. 14: PMID: 36015269
- Update on glasdegib in acute myeloid leukemia - broadening horizons of Hedgehog pathway inhibitors. | Fersing, C. and Mathias, F. 2022. Acta Pharm. 72: 9-34. PMID: 36651529
- Recommendations on the use of azole antifungals in hematology-oncology patients. | Azanza, JR., et al. 2023. Rev Esp Quimioter. 36: 236-258. PMID: 37017117
- Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. | Sekeres, MA., et al. 2023. Leukemia. 37: 2017-2026. PMID: 37604981
Inhibitor of:
C2CD3, DAND5, DISP1, DISP2, HATH-1, HDRP, hedgehog, HH, HIP1, HoxB5, LMBR1, MESP2, Olr1125, patched, PTCHD1, PTCHD3, PTCHD4, Shh, Smo, smoothened, Su(fu), V1RG12, VAX1, and Zic5.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Glasdegib, 5 mg | sc-507353 | 5 mg | $165.00 |